An observational study in Diabetic Foot Ulcers (DFUs), sponsored by ConvaTec Inc.. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.
Sponsored by ConvaTec Inc. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 60 studies in Diabetic Foot with a site in United Kingdom — 5 open to participants now, 8 under way, none of them phase 3. Diabetic Foot · United Kingdom.
Among the 60 studies in Diabetic Foot with a site in United Kingdom, this one is the 7th largest by planned enrollment of the 15 observational ones that give a count, is the only one that started in 2026, is one of 15 observational ones, and was the 60th registered.
1,079 studies on the registry are indexed under Diabetic Foot; 221 are open to participants now.
Browse Diabetic Foot studies →5 of the 60 studies in Diabetic Foot with a site in United Kingdom are open now. Recruiting first, the newest first:
Diabetis JSC · Sites in United Kingdom, Lithuania
Ages 18+
Community Pharmacology Services Ltd · Sites in United Kingdom
Ages 18+
Royal Free Hospital NHS Foundation Trust · Sites in United Kingdom
Ages 18–100
Medical Intelligence Group · Sites in United Kingdom
Ages 18+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 139 Diabetic Foot studies recruiting now, 98 (71%) set no upper age limit and 12 (9%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
60 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 7 · Phase 3 9 · Phase 4 3
First in 2006; this study’s year is marked. 1 started in 2026.
This study's planned enrollment of 102 is close to the median of 100 across 191 observational studies indexed under Diabetic Foot.
Median enrollment 100 across the 45 interventional studies, 100 across the 15 observational. Of the 46 that completed or were terminated, 18 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
31 of 60 have an industry lead sponsor. The 10 most frequent:
ConvaTec Inc. is the lead sponsor of 46 studies on the registry; 4 are open to participants now.
ConvaTec Inc. has 8 studies filed under Diabetic Foot — fewer than ten, so there is no comparison to draw.
4 of the studies in Diabetic Foot with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05762432Community Pharmacology Services LtdDiabetic Foot Ulcer Research Study | 2026-12-01 |
| NCT07300163Diabetis JSCFeetSee Thermal Images Collection Protocol in Diabetes Patients | 2027-05-30 |
| NCT05007301Firstkind LtdGeko™ Cross Therapy Registry - Wound | 2027-09 |
| NCT07438951ConvaTec Inc.Efficacy and Safety of a Nitric Oxide Generating Dressing for Diabetic Foot Ulcers (ONWARD) | 2027-09 |
Add all 4 to your calendar (.ics) → With an account.
Among the 60 studies in Diabetic Foot with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Real world evidence study on the performance and safety of a nitric oxide generating dressing on the treatment of diabetic foot ulcers
The criteria were revised on the registry on Oct 26, 2026. See what changed
All subjects over the age of 18 years with a non-healing DFU (defined as failing to progress on a healing trajectory in the previous 4 weeks prior to enrolment) and treated with ConvaNiox (EDX110) will be screened for eligibility based on medical record review and discussions with the subject and their treating physician.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
IC-1 - Subjects at least 18 years old and willing to participate in all procedures and follow-up evaluations necessary to complete the study
IC-2 - The subject must have either type 1 or type 2 diabetes and a diabetes-related ulcer meeting all the following characteristics:
IC-2a Classified as University of Texas (UT) Classification Grade 1 stages A-D IC-2b At or below the level of malleolus IC-2c Neuropathic or neuroischemic etiology confirmed through Electronic Medical Records (EMR) IC-2d Ulcer surface area between ≥1 and ≤25 cm² IC-2e For subjects who have more than one ulcer, the largest ulcer will be the study ulcer
IC-3 Non-infected and infected ulcers are eligible for inclusion, with infection being classified using the International Working Group on the Diabetic Foot (IWGDF) Infection guidelines.
Only PEDIS 2 infections are permitted. Mild superficial skin and soft tissue infections with no systemic manifestations, characterized by erythema >0.5 but \<2 cm from the wound margin and/or other local signs of infection (swelling, induration, tenderness, increased warmth, or purulent discharge), without involvement of deeper tissues (e.g., tendon, muscle, joint, or bone).
IC-4 Adequate arterial supply in the lower extremity as defined by Wound, Ischemia, foot Infection (WIfI) Ischemia grade 0-1;
Exclusion Criteria:
EC-1 Ulcers that are tunnelling or have cavities (>10mm in depth)
EC-2 An ulcer that is actively bleeding. Subjects may be re-screened once active bleeding has stopped
EC-3 Subjects taking any medication known to inhibit wound closure including chemotherapy and immunomodulatory biological agents. The use of systemic \<10mg/day is permitted
EC-4 Active Charcot foot
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: ConvaNiox
At each visit subjects will receive their Standard of Care (SoC) treatment for their DFU, but instead of their normal primary dressing they will receive an application of ConvaNiox (EDX110).
Percentage area reduction
Difference between wound area at day 0 and 12 weeks of treatment
Time frame: at 12 weeks
Incidence of wound closure
Difference between wound area at day 0 and 12 weeks of treatment
Time frame: at 12 weeks
Percentage area reduction
Difference between wound area at day 0 and 4 weeks of treatment
Time frame: at 4 weeks
Incidence of >50% percentage area reduction
Difference between wound area at day 0 and 4 weeks of treatment
Time frame: at 4 weeks
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2026 (actual). Primary completion is estimated for Sep 2027, 12 months after the start.
Of 90 observational studies under Diabetic Foot, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 59. This study's planned 12 months is below that.
Start moved once since we started tracking on Sep 25, 2026: Jul 2026 → Sep 2026, on Oct 26, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.